reports
Array Technologies Closes Upsized Offering of Its 2.875% Convertible S...
Array Technologies Closes Upsized Offering of Its 2.875% Convertible Senior Notes $345 million raised; approximately $334 million of net proceeds$233 million of term loan outstanding balance to be repaid with proceeds$78 million of proceeds used to repurchase $100 million principal of 1.00% Convertible Senior Notes due 2028$35 million of proceeds used to acquire Capped Calls elevating conversion price to $12.74 per share ALBUQUERQUE, N.M., June 27, 2025 (GLOBE NEWSWIRE) -- ARRAY Technologies, Inc. (NASDAQ: ARRY) (the “Company” or “ARRAY”) today announced the closing of its previously ann...
Palomar and Neptune Partner to Accelerate Growth in U.S. Flood Insuran...
Palomar and Neptune Partner to Accelerate Growth in U.S. Flood Insurance Market ~ Palomar to Appoint Neptune as Exclusive Managing General Agent for Flood Insurance ~ LA JOLLA, Calif. and ST. PETERSBURG, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (“Palomar” NASDAQ: PLMR), a leading specialty insurer, and Neptune Flood (“Neptune”), the largest provider of private flood insurance in the United States, today announced a strategic partnership under which Neptune will become Palomar’s exclusive managing general agent for flood insurance. Palomar will continue its longstan...
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Ac...
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025 BOSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that three late-breaking abstracts have been accepted for presentation at The Endocrine Society’s Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. In a live oral presentation, Susan Phillips, M.D., Pediatric Endocrinolog...
- Abe Rimatzki
- Seth Basham
TSLA TESLA INC
PEGA PEGASYSTEMS INC.
NVDA NVIDIA CORPORATION
KURA KURA ONCOLOGY INC.
BLDR BUILDERS FIRSTSOURCE INC.
WVE WAVE LIFE SCIENCES
PTGX PROTAGONIST THERAPEUTICS
AAPL APPLE INC.
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
RBLX ROBLOX
ATXS ASTRIA THERAPEUTICS INC
MLTX MOONLAKE IMMUNOTHERAPEUTICS
SOUN SOUNDHOUND AI INC
NATL NCR ATLEOS CORPORATION
Array Technologies Announces Pricing of Upsized Offering of Convertibl...
Array Technologies Announces Pricing of Upsized Offering of Convertible Senior Notes ALBUQUERQUE, N.M., June 24, 2025 (GLOBE NEWSWIRE) -- Array Technologies, Inc. (NASDAQ: ARRY) (the “Company” or “ARRAY”) today announced that it has priced an upsized offering of $300 million in aggregate principal amount of 2.875% convertible senior notes due 2031 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”). ARRAY has also granted the initial...
Array Technologies Announces Proposed Private Offering of $250 Million...
Array Technologies Announces Proposed Private Offering of $250 Million of New Convertible Senior Notes ALBUQUERQUE, N.M., June 24, 2025 (GLOBE NEWSWIRE) -- Array Technologies, Inc. (NASDAQ: ARRY) (the “Company” or “ARRAY”) today announced that, subject to market conditions, it intends to offer $250 million in aggregate principal amount of convertible senior notes due 2031 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”). ARRAY also...
- Wedbush Research
- Jay McCanless
ARRAY Technologies to Acquire APA Solar
ARRAY Technologies to Acquire APA Solar Advancing ARRAY’s balance of systems strategy with leading engineered foundation solutions and fixed-tilt mounting systems Adds domestically manufactured engineered foundations and fixed-tilt solutions to product portfolio, expanding addressable market by nearly 40% Enables integrated tracker + foundation system to address challenging soil conditions, which does not require specialized equipment to install Expands U.S. manufacturing capabilities with new Ohio manufacturing facility Transaction enterprise value of approximately $179 million repres...
Rhythm Pharmaceuticals Inc: 1 director
A director at Rhythm Pharmaceuticals Inc sold/sold after exercising options 3,957 shares at 67.190USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's d...
- Jay McCanless
- Wedbush Research
PEGA PEGASYSTEMS INC.
KURA KURA ONCOLOGY INC.
ISR ISORAY
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
ORIC ORIC PHARMACEUTICALS
SNOW SNOWFLAKE INC. CLASS A
TNGX TANGO THERAPEUTICS
GLUE INC
JANX MONTE ROSA THERAPEUTICS INC
MLTX JANUX THERAPEUTICS INC
CRBP MOONLAKE IMMUNOTHERAPEUTICS
BCAX CORBUS PHARMACEUTICALS HOLDINGS INC.
BICARA THERAPEUTICS INC.
- Jay McCanless
Palomar Holdings, Inc. Announces Successful Completion of June 1 Reins...
Palomar Holdings, Inc. Announces Successful Completion of June 1 Reinsurance Placement ~ Full-Year 2025 Adjusted Net Income Guidance Increased to $195 Million to $205 Million ~ LA JOLLA, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ: PLMR) (“Palomar” or the “Company”) today announced the successful completion of certain reinsurance programs incepting June 1, 2025, and increased the Company’s full year 2025 adjusted net income guidance. The Company has procured approximately $455 million of incremental limit to support the growth of its Earthquake franchise. Pal...
Palomar Holdings, Inc. Announces Participation in the William Blair 45...
Palomar Holdings, Inc. Announces Participation in the William Blair 45th Annual Growth Stock Conference LA JOLLA, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ: PLMR) (“Palomar”) today announced that Mac Armstrong, Chairman and Chief Executive Officer, and Chris Uchida, Chief Financial Officer, will participate in the William Blair Growth Stock Conference at the Loews Chicago Hotel on Wednesday, June 4, 2025. In addition to participating in one-on-one investor meetings, management is scheduled to present at 1:20 pm Central Time. Interested investors and other pa...
ARRAY Unveils Hail XP: An Industry-Leading Tracker for Extreme Weather...
ARRAY Unveils Hail XP: An Industry-Leading Tracker for Extreme Weather Protection With 77-degree stow, AC-powered control, and integration with ARRAY’s Hail Alert Response system, Hail XP sets a new standard in tracker resilience ALBUQUERQUE, N.M., May 15, 2025 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology products, software and services, today unveiled DuraTrack Hail XP™, the Company’s most advanced tracker designed to withstand extreme hail and wind events. Hail XP builds on ARRAY’s proven Dur...
Rhythm Pharmaceuticals Announces New Data Presentations on Patients wi...
Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program -- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology (ESPE-ESE); 32nd annual European Congress on Obesity (ECO); and the 2025 annual meeting of the Pediatric Endocrine Society (PES 2025) -- ...
- Wedbush Research
XNCR XENCOR INC.
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FTNT FORTINET INC.
FB FACEBOOK INC. CLASS A
CYBR CYBERARK SOFTWARE LTD.
CXW CORECIVIC INC.
CRM SALESFORCE.COM INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
INOD INNODATA
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
CVNA CARVANA CO. CLASS A
SNDK SANDISK CORPORATION
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ZG ZILLOW GROUP INC. CLASS A
ESTC ELASTIC N.V.
SAFE SAFEHOLD INC.
UBER UBER TECHNOLOGIES INC.
SMCI SUPER MICRO COMPUTER
RVMD INC.
GBIO REVOLUTION MEDICINES
U GENERATION BIO
RKT UNITY SOFTWARE
ABNB ROCKET COMPANIES
AI AIRBNB INC. CLASS A
PLTR C3.AI
VRDN PALANTIR TECHNOLOGIES
NUVB VIRIDIAN THERAPEUTICS INC
SNOW NUVATION BIO INC (A)
STX SNOWFLAKE INC. CLASS A
APP SEAGATE TECHNOLOGY HLDGS PLC
CCSI APPLOVIN CORP
GFS CONSENSUS CLOUD SOLUTIONS INC
ALCC GLOBALFOUNDRIES INC
DBD ALTC ACQUISITION CORP
NOW-US DIEBOLD NIXDORF INCORPORATED
SERVICENOW
INC.
- Jay McCanless
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results an...
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 -- -- Topline data from Phase 2 trial of oral MC4R agonist bivamelagon on tr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.